Abstract
Amorphous phases of active pharmaceutical ingredients (APIs) generally possess greater solubility than the crystalline counterparts. This presents them as attractive candidates for enhancing the bioavailability of the sparingly soluble drugs, while the unstable nature of them makes it challenging to reliably evaluate their potential improvement in solubility and utilize them in drug formulations. We have investigated the anodic aluminum oxide (AAO) substrates with nanopores to establish a simple system to examine the solubility increase accompanied by the decrease of the API crystallinity, using ibuprofen (IBU) as a model compound. The fabricated AAO substrates had the average pore diameters: 25, 55, and 370 nm. The AAO substrates with nanopores allowed the solidification of IBU with lower crystallinity. Also, the release behavior directly from the AAO substrates made it possible to estimate the accompanying solubility increase. The amorphous IBU in the 25-nm pores possessed solubility about 6 times higher than the bulk crystalline phase. The present study demonstrated that the nanoporous AAO substrates could be utilized as a straightforward tool to investigate the solubility and stability of the amorphous phases of APIs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
